Life Science Investing Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA
pharmaceutical investing Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
pharmaceutical investing Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
Group Eleven Drills 25.6m of 9.2% Zn+Pb and 28 g/t Ag and Extends Deeper Cu-Ag Zone with 17.4m of 35 g/t Ag and 0.31% Cu at Ballywire Discovery
